Neetu Yoshi Regulatory Approval

Other Announcement

Neetu Yoshi Other Announcement

Neetu Yoshi Limited submitted its quarterly compliance certificate under SEBI Regulation 74(5), confirming dematerialization records from its registrar.

Annual General Meeting

Neetu Yoshi Annual General Meeting

Neetu Yoshi Limited submitted the proceedings of its 6th Annual General Meeting held on September 30, 2026. Key agenda items included adoption of financial statements and director re-appointment.

Business Update

Neetu Yoshi Business Update

Neetu Yoshi Ltd received RDSO prototype approval for its Friction Wedge, enhancing its product portfolio and eligibility to supply the Indian Railways.

Annual Report

Neetu Yoshi Annual Report

Neetu Yoshi Limited submitted its Annual Report for the financial year 2025-26, fulfilling compliance obligations under Regulation 34 of SEBI (LODR) Regulations, 2015.

Capital Structure Change

Neetu Yoshi Capital Structure Change

Neetu Yoshi Limited allotted 26,42,400 warrants at ₹104 each, raising approximately ₹27.48 Crore. The warrants are convertible into equity shares within 18 months.

Value

₹27.48 Cr

Other Announcement

Neetu Yoshi Other Announcement

Neetu Yoshi Ltd filed a statement confirming no deviation or variation in the utilization of proceeds from its IPO for the quarter ended June 30, 2026.

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.